Member Info for Palmsairport

If you go to https://www.boots.com/myhealthchecked-at-home-covid-19-pcr-swab-test-kit-(for-general-use-and-fit-to-fly)-10295700 use your curser to hover over the actual box displaying the image of the product. It will intermittently give you a reading of how many people are looking at the page and how many have purchased from the site (not a store) as a whole in the last 24 hours.

Hi Roly: in terms of upside and downside, I think that could prove to be a great entry point for you. This morning I can buy and the ask price is 1.88. I have been checking the counter on the Boots website and the sales show 50+. To this we can add the direct sales from the MHC website. As others on the board have indicated and given the current situation, the testing is likely to stay for a while and so the concerns which led to the severe drop in the share price appear to have mitigated. I recently watched the 'tailored' presentation they had on BRR Media in late September and they do refer to plans for recruitment and progress moving forward with the new products so the overall outlook looks good. All we can do is wait and see.

https://www.brrmedia.co.uk/broadcasts/614b91723ae1ca74490b265b/myhealthchecked/

Out of interest, I tried purchasing between 2-4.30 this afternoon on Halifax and it was consistently NT, no matter the size of the transaction; however, they were willing to buy my entire holding at 1.69.

Solid advice AG1989; but I was just wondering do you give credence to the possibility that the MMs have, over the last few months and following the release of overwhelmingly positive RNSs, are somehow deliberately holding the SP back for some reason, although I do appreciate that many argue that it's simply a case of the interplay of the buy-sell dynamic.

Today:
'Travel restrictions on flights from Europe may have to return over fear Covid surge on continent could spark new variant'
Tory chief Oliver Dowden said ministers "haven't ruled out" reintroducing measures like quarantine and PCR tests if necessary.

Thanks NicName. 'From the interims they are forecasting a full year loss. Perhaps a relatively small one ATM, but they need to show positive earnings and how'.
It explains why its price is so subdued, for now. But when you think of the fact that the future is renewables across the globe, surely they are well placed to take advantage of their expertise, if the lessons of the past can be learnt from.

From a very confident Colin: ‘There will be a lot more news flow over the coming weeks as this unfolds’
8m 22s
https://www.youtube.com/watch?v=PHSpsVZhhQE

The amazing thing is that even given the huge upside and proof of concept, investors can still get in at ridiculously low prices.

Thanks Goodlife and totally agree: potentially, looking forward, there's a lot more to come from this company. As Jack Bai states 'establishing a significant business from the stablecoin network and applications'. That's the vision and it's backed up by the requisite technology.
Wishing all holders the very best.

Hi SMTrading,

Those sorts of figures are encouraging and probably explain why Penny and the team felt that the income streams for the Covid testing would remain fairly consistent and good.

Yes. It's wait and see for now. The next RNS to drop could provide the answers

If they do get the necessary approval, I am looking forward to learning more about the functionality of GST using the Angra FX license to develop their various products: 'GS Money protocol'; 'GSend remittance gateway'; and GS Money App (see the RNS of the 28th of May 2021). It also mentions in the same RNS that 'The cash reserve will be transparently managed by an EU registered entity that is yet to be established or acquired'. and so an acquisition within the EU zone could be planned. There is certainly ambition here.

https://www.lse.co.uk/rns/GST/wise-mpay-collaboration-agreement-afo17v8lv27b99q.html

Fair points NicName. Still, having all the available information and views is useful and helps us make informed decisions

You're welcome roly12; obviously, we are awaiting not only the introduction of new products in 2022 but also the figures which will enable us to gauge the extent to which MHC was affected by the change of rules regarding the requirements for PCR testing for those returning to the UK, although the company indicates it still expects good levels of income to be maintained for the simple reason that PCR testing for outbound travellers remains in place for many countries. Having said that, the company suggests that its objective was always to use the income from the Covid testing to fund the development of their new range of home tests. The Covid testing was seen as an opportunity to raise income. Over the course of the year, since the contracts with Boots were announced, we hit highs of around 7.45 in mid-April, but are now hovering around the 1.50-1.70 mark. All the best.

Hi roly12

If you go on to the company page for MHC on the London Stock Exchange (at the bottom of the webpage) there is an Equity Research report by SEAL Advisors Ltd. Regarding the research, there is a disclaimer that does state that it was 'prepared on behalf of MyHealthCheckedplc (“MHC” or the “Company”) in conjunction with Oberon Capital (“Oberon”) to provide background information and views about the Company. But it also adds that the report has been produced 'independently' of the Company, adding that the 'forecasts, opinions, and expectations contained herein are entirely those of SEAL.'
The report, which can be downloaded as a pdf is packed with 18 pages of details, graphs and figures which you can go through and is dated the 12th of October 2021. This report may have been flagged on the BB previously, if so, do accept my apologies for posting again. It's well worth the read.

https://www.londonstockexchange.com/stock/MHC/myhealthchecked-plc/company-page

also available from: https://*********************/companies/uk/myhealthchecked-plc/research/seal-advisors-ltd/myhealthchecked-plc-mhc-/3cb9f248-d9f8-4b9f-b17e-30806f9a6493?partner=lse

Certainly no need to cut and run: as has been pointed out numerous times by many posters over the last couple of weeks, the RNS of the 5th of October suggests that the acquisition of Angra Limited and FCA approval will be a gradual process. And that 'Further announcements will be made as appropriate'. If eventually it all goes to plan over the next few months, in the words of Tone Goh, we look forward to hearing more about the accelerated development of GST's 'blockchain enabled neobanking business'.

LondonMarket, as you noted, the TrustPilot reviews are overwhelmingly positive which can only enhance MHC's reputation and this should stand them in good stead, especially with companies such as Boots UK, as they eventually move forward with the introduction of new products. Their website says that tests will 'be made available online and would be viable for over-the-counter purchase', even confidently asserting that 'home testing space is on track to reach $16bn in 2027'. And the Covid PCR testing is likely to continue to figure over the next year, which all bodes well for the gradual recovery of the share price.

https://investors.myhealthchecked.com/business-strategy/business-model

He does deduce that 'with the equity and debt situation almost sorted', 'Lamprell can forge ahead with what it does best and as it builds out the programme under way'.
https://www.share-talk.com/malcys-blog-oil-price-longboat-serica-orcadian-lamprell-chariot-finally/#gs.efw5fn

Looks very good today; the volume is well up: 1,199,339 as of 12.00, although even on the September 29, 2021 when it was trading between 33.45-34.90- and 33.75, its volume was 11,590,082. Let's see what happens on Monday

Ezhik that is some prudent advice for Sharetime43 and it will be worth his reminding himself why he invested in Zephyr in the first place. If it was as a LTH then its prospects are exceptional when compared with other AIM shares. Moreover, it has always delivered over the long term. Ask any of those knowledgable about the history of the share price and fluctuations whenever a RNS has been issued. They will confirm that it in the long run it has always come back. We are now at a seminal juncture in the history of Zephyr and has been pointed out that its current share price is supported by its existing production. If the results are as expected, then we should be in new territory. Best wishes to all and DYOR

Excellent points which underline the potential for LTHs and, of course, surely the Financial Advisers at VSA Capital, Simon Barton / Pascal Wiese, would have provided them with some sort of road map vis a vis FCA approval and ways forward and the suitability of the choice of Angra FX.

+44 (0)20 3005 5000